Catalyst Pharmaceuticals (NASDAQ:CPRX) Announces Earnings Results

Catalyst Pharmaceuticals (NASDAQ:CPRX) issued its quarterly earnings results on Monday. The biopharmaceutical company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15, FiscalAI reports. The firm had revenue of $149.39 million for the quarter, compared to analyst estimates of $149.52 million. Catalyst Pharmaceuticals had a net margin of 36.39% and a return on equity of 36.47%.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX remained flat at $31.15 during midday trading on Monday. The stock had a trading volume of 3,678,652 shares, compared to its average volume of 1,617,556. Catalyst Pharmaceuticals has a 12 month low of $19.05 and a 12 month high of $32.56. The company’s 50 day simple moving average is $25.31 and its two-hundred day simple moving average is $23.93. The company has a market cap of $3.81 billion, a PE ratio of 18.43, a PEG ratio of 0.95 and a beta of 0.72.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently bought and sold shares of CPRX. Advisory Services Network LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter worth approximately $39,000. Quarry LP purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at $40,000. Smartleaf Asset Management LLC boosted its position in Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares during the period. Parkside Financial Bank & Trust grew its holdings in Catalyst Pharmaceuticals by 17.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 469 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $93,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Zacks Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $32.17.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).